Skip to main content
Clinical Trials/ACTRN12612000503820
ACTRN12612000503820
Completed
未知

In preterm infants born at <29 weeks gestation is an emulsion containing a higher amount of docosahexaenoic acid (DHA) more effective than an emulsion with no additional DHA in reducing the incidence of bronchopulmonary dysplasia at 36 weeks post menstrual age?

South Australian Health and Medical Research Institute0 sites1,273 target enrollmentMay 9, 2012

Overview

Phase
未知
Intervention
Not specified
Conditions
Preterm infants
Sponsor
South Australian Health and Medical Research Institute
Enrollment
1273
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 9, 2012
End Date
May 22, 2022
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Born at less than 29 weeks gestational age
  • Within 3 days of commencing enteral feeds
  • Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the infant’s behalf

Exclusion Criteria

  • Infants who have a major congenital or chromosomal abnormality will be excluded from the study
  • Women providing breast milk who are taking supplements providing \>250 mg DHA per day and do not wish to stop taking supplements.
  • Infants participating in another fatty acid study.
  • Infants receiving intravenous lipid emulsions containing fish oil given as early lipid parenteral nutrition support.

Outcomes

Primary Outcomes

Not specified

Similar Trials